Adam S. Mullis

Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression

Michelle L. Luo, Adam S. Mullis, Ryan T. Leenay et al. · Nucleic Acids Research · 2014 · 257 citations · Full text

Transcriptional Regulation, Systems Biology, Engineering +13

Nanotherapeutic provides dose sparing and improved antimicrobial activity against Brucella melitensis infections

Paul Lueth, Shannon L. Haughney, Andrea M. Binnebose et al. · Journal of Controlled Release · 2018 · 32 citations

Nanomedicine, Nanotherapeutics, Engineering +15

Data Analytics Approach for Rational Design of Nanomedicines with Programmable Drug Release

Adam S. Mullis, Scott Broderick, Andrea M. Binnebose et al. · Molecular Pharmaceutics · 2019 · 28 citations

Engineering, Biomedical Engineering, Nanomedicine +16

Mitochondria dysregulation contributes to secondary neurodegeneration progression post-contusion injury in human 3D in vitro triculture brain tissue model

Volha Liaudanskaya, Nicholas J. Fiore, Yang Zhang et al. · Cell Death and Disease · 2023 · 24 citations · Full text

Traumatic Brain Injury, Mitochondrial Dysfunction, Cell Death +19

Nanomedicines to counter microbial barriers and antimicrobial resistance

Adam S. Mullis, Nathan Peroutka‐Bigus, Kruttika S. Phadke et al. · Current Opinion in Chemical Engineering · 2021 · 19 citations

Nanomedicine, Engineering, Nanobiotechnology +8